

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jtd-23-348">https://dx.doi.org/10.21037/jtd-23-348</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists and pulmonary physicians who are interested in this study.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: <a href="mailto:songzb@zjcc.org.cn">songzb@zjcc.org.cn</a> .
10	Any other restrictions?	We will carefully evaluate each request and assess the potential benefits and risks involved. Based on this evaluation, we will provide the data that can be shared in a manner that is both useful and ethical.